Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02430480|
Recruitment Status : Active, not recruiting
First Posted : April 30, 2015
Last Update Posted : June 3, 2019
- There are several ways to treat prostate cancer. Researchers want to see how well a certain kind of imaging helps detect prostate cancer. They also want to see if a particular drug combination used before surgery will benefit people with prostate cancer that hasn t spread in the body (non-metastatic). The combination will be androgen deprivation therapy and enzalutamide.
- The combination of androgen deprivation therapy and enzalutamide has been shown to make patients with advanced (metastatic disease) live longer. The investigators want to see if using it earlier can increase cure rate of surgery and identify genetic or molecular characteristics that are associated with better outcomes.
- To develop better ways of detecting prostate cancer before and after pre-operative treatment.
- Men at least 18 years old with non-metastatic prostate cancer. They must be candidates for a radical prostatectomy.
- Participants will be screened with medical history, physical exam, and blood tests. They will have scans and X-rays.
- Before starting the study drugs, participants will have:
- Vital signs taken, medical history, and blood tests.
- ECG heart test, with patches stuck on the skin.
- Small piece of tumor removed (biopsy) using image guidance from MRI and ultrasound.
- 3T mpMRI. Participants will lie on a table that slides into a metal cylinder. A probe will be inserted in the <TAB>rectum. They will be in the scanner for about 60 minutes, lying still. The scanner makes loud knocking <TAB>sounds. Participants will get earplugs.
- Participants will take the 2 study drugs for 6 months.
- Enzalutamide is taken as 4 pills once a day.
- Androgen deprivation therapy is given by injection 2 times over 6 months.
- During these 6 months, participants will visit the clinic monthly. They will have physical exam, vital signs, and blood drawn.
- After finishing the study drugs, participants will have another 3T mpMRI. Then they will have prostate removal surgery.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Goserelin Procedure: mpMRI||Phase 2|
- Most men diagnosed with prostate cancer will present with intermediate or high-risk disease
- Many develop castrate resistant prostate cancer (CRPC) as curative strategies are often
- Treatment options typically involve radical prostatectomy (RP) or radiation therapy (RT) in combination with androgen deprivation therapy (ADT)
- Even when cancers are initially sensitive to ADT, resistance ultimately emerges either through clonal selection or through a variety of adaptive mechanisms (secondary resistance).
- The recent introduction of novel androgen pathway inhibitors offers an opportunity to potentially improve the cure rate of men with intermediate and high risk localized prostate cancer
- There remains a great need for improved techniques to determine mechanisms of treatment response and resistance.
-To test the feasibility of multi parametric magnetic resonance imaging (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide.
- Patients with nonmetastatic castration sensitive prostate cancer with intermediate or high-risk features
- Patients with testosterone levels greater than or equal to 100 ng/dL.
- ECOG 0-1.
- Patients will be treated with ADT and enzalutamide for 6 months
- Two 3T mpMRI endorectal examinations (One at screening and after 6 month of treatment)
- Screening biopsy (MR/US guided) samples
- Standard of care prostatectomy(RP) following post treatment mpMRI
- All tumor specimens will undergo genomic analysis
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer|
|Actual Study Start Date :||June 3, 2015|
|Estimated Primary Completion Date :||December 1, 2019|
|Estimated Study Completion Date :||June 1, 2020|
Experimental: 1/Arm 1
Patients will have an mpMRI guided biopsy, then receive enzalutamide and goserelin SC treatment for 6 months followed by a second mpMRI examination.
10.8mg administered subcutaneously every 12 weeks (2 doses)
Multiparametric MRI - One at baseline and after 6 months of treatment
- Feasiblity of mpMRI before and after surgery [ Time Frame: 6 months ]localization and detections of focal prostate cancer before and aftertreatment with mpMRI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02430480
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||William L Dahut, M.D.||National Cancer Institute (NCI)|